This Test is a specialized laboratory test performed on tissue samples to evaluate the Ki-67 protein, a marker associated with cell proliferation (growth and division).
Ki-67 is present in actively dividing cells, and its level reflects how quickly tumor cells are growing. A high Ki-67 index indicates rapid cell proliferation and is often associated with more aggressive tumors, while a low index suggests slower growth.
The Ki67 IHC (Immunohistochemistry) test detects the Ki-67 protein in tissue samples using immunohistochemical staining. Ki-67 is a marker of cell proliferation, meaning it indicates how actively cells are dividing.
The test is commonly performed on biopsy or surgical tissue specimens as part of the pathological evaluation of tumors. The percentage of cells showing Ki-67 staining, known as the Ki-67 proliferation index, can provide information about how rapidly tumor cells are multiplying.
Ki-67 assessment can be particularly useful in the evaluation and classification of certain breast cancers, neuroendocrine tumors, lymphomas, and other malignancies. It may also help healthcare professionals assess tumor behavior, determine tumor grade in appropriate cancers, and support treatment planning. Always interpret results together with the patient's pathology findings and other clinical information.
1. What is the Ki67 IHC test?
Ki67 IHC is an immunohistochemistry test performed on tissue to detect the Ki-67 protein, which is associated with actively dividing cells. It helps pathologists estimate the proliferation rate of a tumor.
2. What does a high Ki-67 index mean?
A higher Ki-67 index generally indicates that a greater proportion of cells are actively dividing. In some cancers, this may be associated with more rapidly growing or aggressive disease. However, the significance depends on the type of tumor and the clinical context.
3. Is Ki-67 used to diagnose cancer by itself?
No. Ki-67 is not usually used as a standalone cancer diagnostic test. It is interpreted along with tissue morphology, other IHC markers, imaging, clinical findings, and other pathology results to help characterize a tumor.